Cargando…
Ophthalmic Manifestations of Newly Diagnosed Acute Leukemia Patients in a Tunisian Cohort
PURPOSE: To describe ocular manifestations of acute leukemia in a Tunisian cohort and to assess the associations between ophthalmic findings and epidemiological, clinical, and biological features of the disease. METHODS: A prospective study included patients newly diagnosed with acute leukemia refer...
Autores principales: | , , , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Dove
2022
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9560867/ https://www.ncbi.nlm.nih.gov/pubmed/36249442 http://dx.doi.org/10.2147/OPTH.S365648 |
_version_ | 1784807848007434240 |
---|---|
author | Sayadi, Jihene Gouider, Dhouha Allouche, Yasmine Choura, Racem Cherni, Ines Sayadi, Malek Benneji, Hend Zghal, Imene Malek, Ines Nacef, Leila |
author_facet | Sayadi, Jihene Gouider, Dhouha Allouche, Yasmine Choura, Racem Cherni, Ines Sayadi, Malek Benneji, Hend Zghal, Imene Malek, Ines Nacef, Leila |
author_sort | Sayadi, Jihene |
collection | PubMed |
description | PURPOSE: To describe ocular manifestations of acute leukemia in a Tunisian cohort and to assess the associations between ophthalmic findings and epidemiological, clinical, and biological features of the disease. METHODS: A prospective study included patients newly diagnosed with acute leukemia referred to our clinics between January 2019 and July 2020. All patients underwent a complete ophthalmic evaluation and spectral-domain optical coherence tomography (SD-OCT) at presentation, then every two months during one year. We defined two groups: Group 1 included patients with leukemic ophthalmopathy and group 2 included patients with normal ophthalmic examination. RESULTS: Forty-six patients were enrolled. The mean age of patients was 32.1±15.3 years. The sex ratio M/F was 1.55 (28 male patients and 18 females). Twenty-nine patients (63%) had acute myeloid leukemia (AML), and 17 (37%) had acute lymphoblastic leukemia (ALL). The average follow-up was 9.1 months (range: 3–12 months). We observed ophthalmic manifestations in 28 patients (61%). Among them, 17 (61%) had vision-threatening complications. The posterior segment was the most common site of ocular involvement (82% of group1). Primary leukemic infiltration (Disc edema, ptosis, exophthalmos) was present in 13 eyes (14.1%). Twenty-seven eyes (29.3%) had secondary involvement lesions (Subconjunctival hemorrhage, periorbital ecchymosis, retinal/sub-hyaloid hemorrhage, dilated/tortuous veins). Twenty-one eyes (22.8%) showed other ocular manifestations which etiopathogenesis is not yet fully understood (White-centred hemorrhages, cotton-wool spots, serous retinal detachment, hemorrhagic pigment epithelial detachment). Leukemic retinopathy was significantly more frequent in adults (23/39 and 1/7 in adult and pediatric groups, respectively; p=0.003). Patients suffering from AML were more likely to have secondary ocular involvement (20/29 and 7/17 in AML and ALL patients, respectively; p=0.047). Retinal hemorrhages were statistically associated with anemia and thrombocytopenia (p=0.041 and p=0.034; respectively). CONCLUSION: Leukemic ophthalmopathy seems to be frequent and may lead to severe visual impairment. An ophthalmic assessment complemented with SD-OCT has paramount importance in all newly diagnosed acute leukemic patients. |
format | Online Article Text |
id | pubmed-9560867 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2022 |
publisher | Dove |
record_format | MEDLINE/PubMed |
spelling | pubmed-95608672022-10-15 Ophthalmic Manifestations of Newly Diagnosed Acute Leukemia Patients in a Tunisian Cohort Sayadi, Jihene Gouider, Dhouha Allouche, Yasmine Choura, Racem Cherni, Ines Sayadi, Malek Benneji, Hend Zghal, Imene Malek, Ines Nacef, Leila Clin Ophthalmol Original Research PURPOSE: To describe ocular manifestations of acute leukemia in a Tunisian cohort and to assess the associations between ophthalmic findings and epidemiological, clinical, and biological features of the disease. METHODS: A prospective study included patients newly diagnosed with acute leukemia referred to our clinics between January 2019 and July 2020. All patients underwent a complete ophthalmic evaluation and spectral-domain optical coherence tomography (SD-OCT) at presentation, then every two months during one year. We defined two groups: Group 1 included patients with leukemic ophthalmopathy and group 2 included patients with normal ophthalmic examination. RESULTS: Forty-six patients were enrolled. The mean age of patients was 32.1±15.3 years. The sex ratio M/F was 1.55 (28 male patients and 18 females). Twenty-nine patients (63%) had acute myeloid leukemia (AML), and 17 (37%) had acute lymphoblastic leukemia (ALL). The average follow-up was 9.1 months (range: 3–12 months). We observed ophthalmic manifestations in 28 patients (61%). Among them, 17 (61%) had vision-threatening complications. The posterior segment was the most common site of ocular involvement (82% of group1). Primary leukemic infiltration (Disc edema, ptosis, exophthalmos) was present in 13 eyes (14.1%). Twenty-seven eyes (29.3%) had secondary involvement lesions (Subconjunctival hemorrhage, periorbital ecchymosis, retinal/sub-hyaloid hemorrhage, dilated/tortuous veins). Twenty-one eyes (22.8%) showed other ocular manifestations which etiopathogenesis is not yet fully understood (White-centred hemorrhages, cotton-wool spots, serous retinal detachment, hemorrhagic pigment epithelial detachment). Leukemic retinopathy was significantly more frequent in adults (23/39 and 1/7 in adult and pediatric groups, respectively; p=0.003). Patients suffering from AML were more likely to have secondary ocular involvement (20/29 and 7/17 in AML and ALL patients, respectively; p=0.047). Retinal hemorrhages were statistically associated with anemia and thrombocytopenia (p=0.041 and p=0.034; respectively). CONCLUSION: Leukemic ophthalmopathy seems to be frequent and may lead to severe visual impairment. An ophthalmic assessment complemented with SD-OCT has paramount importance in all newly diagnosed acute leukemic patients. Dove 2022-10-14 /pmc/articles/PMC9560867/ /pubmed/36249442 http://dx.doi.org/10.2147/OPTH.S365648 Text en © 2022 Sayadi et al. https://creativecommons.org/licenses/by-nc/3.0/This work is published and licensed by Dove Medical Press Limited. The full terms of this license are available at https://www.dovepress.com/terms.php and incorporate the Creative Commons Attribution – Non Commercial (unported, v3.0) License (http://creativecommons.org/licenses/by-nc/3.0/ (https://creativecommons.org/licenses/by-nc/3.0/) ). By accessing the work you hereby accept the Terms. Non-commercial uses of the work are permitted without any further permission from Dove Medical Press Limited, provided the work is properly attributed. For permission for commercial use of this work, please see paragraphs 4.2 and 5 of our Terms (https://www.dovepress.com/terms.php). |
spellingShingle | Original Research Sayadi, Jihene Gouider, Dhouha Allouche, Yasmine Choura, Racem Cherni, Ines Sayadi, Malek Benneji, Hend Zghal, Imene Malek, Ines Nacef, Leila Ophthalmic Manifestations of Newly Diagnosed Acute Leukemia Patients in a Tunisian Cohort |
title | Ophthalmic Manifestations of Newly Diagnosed Acute Leukemia Patients in a Tunisian Cohort |
title_full | Ophthalmic Manifestations of Newly Diagnosed Acute Leukemia Patients in a Tunisian Cohort |
title_fullStr | Ophthalmic Manifestations of Newly Diagnosed Acute Leukemia Patients in a Tunisian Cohort |
title_full_unstemmed | Ophthalmic Manifestations of Newly Diagnosed Acute Leukemia Patients in a Tunisian Cohort |
title_short | Ophthalmic Manifestations of Newly Diagnosed Acute Leukemia Patients in a Tunisian Cohort |
title_sort | ophthalmic manifestations of newly diagnosed acute leukemia patients in a tunisian cohort |
topic | Original Research |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9560867/ https://www.ncbi.nlm.nih.gov/pubmed/36249442 http://dx.doi.org/10.2147/OPTH.S365648 |
work_keys_str_mv | AT sayadijihene ophthalmicmanifestationsofnewlydiagnosedacuteleukemiapatientsinatunisiancohort AT gouiderdhouha ophthalmicmanifestationsofnewlydiagnosedacuteleukemiapatientsinatunisiancohort AT alloucheyasmine ophthalmicmanifestationsofnewlydiagnosedacuteleukemiapatientsinatunisiancohort AT chouraracem ophthalmicmanifestationsofnewlydiagnosedacuteleukemiapatientsinatunisiancohort AT cherniines ophthalmicmanifestationsofnewlydiagnosedacuteleukemiapatientsinatunisiancohort AT sayadimalek ophthalmicmanifestationsofnewlydiagnosedacuteleukemiapatientsinatunisiancohort AT bennejihend ophthalmicmanifestationsofnewlydiagnosedacuteleukemiapatientsinatunisiancohort AT zghalimene ophthalmicmanifestationsofnewlydiagnosedacuteleukemiapatientsinatunisiancohort AT malekines ophthalmicmanifestationsofnewlydiagnosedacuteleukemiapatientsinatunisiancohort AT nacefleila ophthalmicmanifestationsofnewlydiagnosedacuteleukemiapatientsinatunisiancohort |